Clinical Trial: Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

U.S., June 4 -- ClinicalTrials.gov registry received information related to the study (NCT07622706) titled 'Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma' on May 28.

Brief Summary: An Open-label, Single-arm, Phase II Clinical Study of Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Study Start Date: May 30

Study Type: INTERVENTIONAL

Condition: NSCLC EGFR Positive Non-small Cell Lung Cancer Neoadjuvant Therapy

Intervention: DRUG: Firmonertinib 80mg qd oral for 8 weeks.

Participations will receive the drug treatments preoperatively: Firmonertinib 80mg qd oral for 8 weeks. Radical tumor resection will be completed 3-4 weeks aft...